Managing Director Diane Wehner of Teton Advisors believes Illumina, Inc. (ILMN) will continue to benefit from its exposure to the genetics sequencing segment.
“[Illumina] is a medical technology company that’s a leader in instruments used in genetic sequencing. DNA sequencing is a rapidly growing segment within health care, as the industry moves toward what we’ve all been hearing about in personalized medicine,” Wehner said.
FOR MORE INFORMATION ON THIS INTERVIEW CLICK HERE.
Illumina, Inc.’s stock is up 27% year to date and has appreciated over 270% in the past five years, Wehner says. As Illumina continues to innovate, she expects the company to solidify itself as leader in the space.
“They introduced 12 new game-changing products and services at the beginning of this year, which solidifies their technology lead in this space where they face very little competition. We expect the momentum to continue for the company in this subsegment of health care, which is conservatively estimated to reach about $20-plus billion in the next couple of years,” Wehner said.
Codex DNA (NASDAQ:DNAY) CEO Todd Nelson Details the Investment Opportunity for mRNA and DNA Replication
March 28, 2022
Illumina, Inc. (ILMN) is Still a Robust Growth Story
August 10, 2015
Illumina, Inc. (NASDAQ:ILMN) Still Growing at Double-Digit Rate
March 21, 2016
Follow High Growth, High Return Stocks like Illumina (NASDAQ:ILMN): Interviews with Professional Investors
January 23, 2018
Illumina (NASDAQ:ILMN) Has a New Complementary Technology Produced by Bionano Genomics (NASDAQ:BNGO)
October 29, 2019
